activation during lorlatinib treatment mediates initial cell survival in
1. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged
advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol.
2019;30(7):1121-1126.
2. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-
positive non-small-cell lung cancer: integrated analysis of three
phase 1-2 trials. Lancet Oncol. 2020;21(2):261-270.
3. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung
cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet
Oncol. 2017;18(12):1590-1599.
4. Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-
positive non-small-cell lung cancer: a multicentre, open-label,
single-arm, phase 1-2 trial. Lancet Oncol. 2019;20(12):1691-1701.
5. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M,
Dzięgiel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers. 2021;13(18):4705.
6. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer.
J Thorac Oncol. 2017;12(11):1611-1625.
7. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting
ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res.
2012;18(17):4570-4579.
8. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and
selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA.
2015;112(11):3493-3 498.
9. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-
7-a mino-1 2-f luoro-2 ,10,16-t rimethyl-1 5-o xo-1 0,15,16,17-tetrahydro-2 H-8 ,4-( metheno)pyrazolo[4,3-h][2,5,11]-b enzoxa
diazacyclotetradecine-3-c arbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros
oncogene 1 (ROS1) with preclinical brain exposure and broad-
spectrum potency against ALK-resistant mutations. J Med Chem.
2014;57(11):4720-4744.
10. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or
crizotinib in advanced ALK-positive lung cancer. N Engl J Med.
2020;383(21):2018-2029.
11. Guaitoli G, Bertolini F, Bettelli S, et al. Deepening the knowledge
of ROS1 rearrangements in non-small cell lung cancer: diagnosis,
treatment, resistance and concomitant alterations. Int J Mol Sci.
2021;22(23):12867.
12. Lin JJ, Choudhury NJ, Yoda S, et al. Spectrum of mechanisms of
resistance to crizotinib and Lorlatinib in ROS1 fusion-positive lung
cancer. Clin Cancer Res. 2021;27(10):2899-2909.
13. Facchinetti F, Loriot Y, Kuo MS, et al. Crizotinib-resistant ROS1
mutations reveal a predictive kinase inhibitor sensitivity model
response to lorlatinib through AKT signaling. Thus, combined treatments against both YAP1 and ROS1 could be an effective curative
strategy for ROS1-rearranged NSCLC.
AU T H O R C O N T R I B U T I O N S
Conception and design: M. Yamazoe, H. Ozasa, T. Tsuji. Development
of methodology: M. Yamazoe, H. Ozasa, T. Tsuji, W. Aoki. Acquisition
of data: M. Yamazoe, H. Ozasa, W. Aoki. Analysis and interpretation
of data: M. Yamazoe, H. Ozasa, W. Aoki. Writing, review, and/or revision of the manuscript: M. Yamazoe, H. Ozasa, T. Tsuji, T. Funazo, H.
Yoshida, K. Hashimoto, K. Hosoya, T. Ogimoto, H. Ajimizu, H. Yoshida,
R. Itotani, Y. Sakamori, K. Kuninaga, W. Aoki, T. Hirai. Administrative,
technical, or material support: M. Yamazoe, H. Ozasa, T. Tsuji, T.
Funazo. Study supervision: H. Ozasa, Y. Sakamori, T. Hirai.
AC K N OW L E D G M E N T
The authors acknowledge the Center for Anatomical, Pathological,
and Forensic Medical Research, Graduate School of Medicine, Kyoto
University.
F U N D I N G I N FO R M AT I O N
This study was supported by a Research Fellowship for Young
Scientists of the Japan Society for the Promotion of Science (JSPS)
Grant Number 21 J12463 (M.Y.) and JSPS KAKENHI Grant Number
19 K08601 (H.O.).
C O N FL I C T O F I N T E R E S T
The authors have no conflict of interest.
DATA AVA I L A B I L I T Y S TAT E M E N T
The data generated in this study are available upon request from the
corresponding author.
E T H I C A L A P P R OVA L
The study protocol was approved by the Kyoto University Graduate
School and Faculty of Medicine Ethics Committee (certification nos.
R0996, R2163).
13497006, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.15622 by Cochrane Japan, Wiley Online Library on [23/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
14 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 3 0. 31. 32. 33. for ROS1- and ALK-rearranged lung cancers. Clin Cancer Res.
2016;22(24):5983-5991.
Delgado J, Pean E, Melchiorri D, et al. The European Medicines
Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine
receptor kinase gene fusions and adult patients with non-small-
cell lung cancer harbouring ROS1 rearrangements. ESMO Open.
2021;6(2):100087.
Song A, Kim TM, Kim DW, et al. Molecular changes associated with
acquired resistance to crizotinib in ROS1-rearranged non-small cell
lung cancer. Clin Cancer Res. 2015;21(10):2379-2387.
McCoach CE, Le AT, Gowan K, et al. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin
Cancer Res. 2018;24(14):3334-3347.
Dziadziuszko R, Le AT, Wrona A, et al. An activating KIT mutation
induces crizotinib resistance in ROS1-positive lung cancer. J Thorac
Oncol. 2016;11(8):1273-1281.
Kato Y, Ninomiya K, Ohashi K, et al. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring
ROS1 fusions. Cancer Sci. 2018;109(10):3149-3158.
Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug
resistance mechanisms in lung cancer targeted therapy. J Hematol
Oncol. 2019;12(1):134.
Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell.
2010;141(1):69-8 0.
De Conti G, Dias MH, Bernards R. Fighting drug resistance
through the targeting of drug-tolerant persister cells. Cancers.
2021;13(5):1118.
Cabanos HF, Hata AN. Emerging insights into targeted therapy-
tolerant persister cells in cancer. Cancers. 2021;13(11):2666.
Taniguchi H, Yamada T, Wang R, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Nat Commun. 2019;10(1):259.
Wang R, Yamada T, Kita K, et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat Commun. 2020;11(1):4607.
Tsuji T, Ozasa H, Aoki W, et al. YAP1 mediates survival of ALK-
rearranged lung cancer cells treated with alectinib via pro-apoptotic
protein regulation. Nat Commun. 2020;11(1):74.
Tanimura K, Yamada T, Horinaka M, et al. Inhibition of c-Jun N-
terminal kinase signaling increased apoptosis and prevented the
emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small
cell lung cancer. Cancer Lett. 2021;522:119-128.
Tanimura K, Yamada T, Okada K, et al. HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-
rearranged lung cancer with mesenchymal features. Oncologia.
2022;6:5.
Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for
detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn.
2014;16(2):229-243.
Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med.
2013;368(25):2395-2401.
Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export
is a druggable vulnerability in KRAS-mutant lung cancer. Nature.
2016;538(7623):114-117.
Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell
Physiol. 2011;300(4):C723-C742.
Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474(7350):179-183.
Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-1971.
3 4. Yu LY, Tseng TJ, Lin HC, et al. Synthetic dysmobility screen unveils
an integrated STK40-YAP-MAPK system driving cell migration. Sci
Adv. 2021;7(31):eabg2106.
35. Coggins GE, Farrel A, Rathi KS, et al. YAP1 mediates resistance to
MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signaling. Cancer Res. 2019;79(24):6204-6214.
36. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300-1305.
37. Lee HC, Ou CH, Huang YC, et al. YAP1 overexpression contributes
to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene.
2021;40(13):2407-2421.
38. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the
welfare and use of animals in cancer research. Br J Cancer.
2010;102(11):1555-1577.
39. Brown JS, Banerji U. Maximising the potential of AKT inhibitors as
anti-c ancer treatments. Pharmacol Ther. 2017;172:101-115.
4 0. Tumaneng K, Schlegelmilch K, Russell RC, et al. YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing
PTEN via miR-29. Nat Cell Biol. 2012;14(12):1322-1329.
41. Wang C, Gu C, Jeong KJ, et al. YAP/TAZ-mediated upregulation of
GAB2 leads to increased sensitivity to growth factor-induced activation of the PI3K pathway. Cancer Res. 2017;77(7):1637-1648.
42. Lin Z, Zhou P, von Gise A, et al. Pi3kcb links Hippo-YAP and PI3K-
AKT signaling pathways to promote cardiomyocyte proliferation
and survival. Circ Res. 2015;116(1):35-45.
43. Mello SS, Valente LJ, Raj N, et al. A p53 Super-tumor Suppressor
Reveals a Tumor Suppressive p53-P tpn14-Yap Axis in Pancreatic
Cancer. Cancer Cell. 2017;32(4):460-473.
4 4. Di Agostino S, Sorrentino G, Ingallina E, et al. YAP enhances the
pro-proliferative transcriptional activity of mutant p53 proteins.
EMBO Rep. 2016;17(2):188-201.
45. Shi Z, Moult J. Structural and functional impact of cancer-related
missense somatic mutations. J Mol Biol. 2011;413(2):495-512.
46. Vaishnavi A, Schubert L, Rix U, et al. EGFR mediates responses to
small-molecule drugs targeting oncogenic fusion kinases. Cancer
Res. 2017;77(13):3551-3563.
47. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo
signaling and beyond. Physiol Rev. 2014;94(4):1287-1312.
48. Huh HD, Kim DH, Jeong HS, Park HW. Regulation of TEAD transcription factors in cancer biology. Cell. 2019;8(6):600.
49. Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of
cancer. Cancer Cell. 2016;29(6):783-8 03.
50. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway
regulation by cell morphology and stress fibers. Development.
2011;138(18):3907-3914.
S U P P O R T I N G I N FO R M AT I O N
Additional supporting information can be found online in the
Supporting Information section at the end of this article.
How to cite this article: Yamazoe M, Ozasa H, Tsuji T, et al.
Yes-associated protein 1 mediates initial cell survival during
lorlatinib treatment through AKT signaling in ROS1-
rearranged lung cancer. Cancer Sci. 2022;00:1-15.
doi:10.1111/cas.15622
13497006, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.15622 by Cochrane Japan, Wiley Online Library on [23/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
15
YAMAZOE et al.
...
論文の公開元へ
